FDA has announced it has expanded the approved use of Humira (adalimumab), manufactured by Abbott Laboratories, to include treatment of moderate-to-severe ulcerative colitis in adults, according to a ...

AbbVie has received European Commission approval of its anti-inflammation drug Skyrizi for the treatment of adult patients with moderately to severely active ulcerative colitis, the pharmaceutical ...

AbbVie, Inc. ABBV announced top-line data from the phase III maintenance study, COMMAND, which evaluated its IL-23 drug Skyrizi (risankizumab) in adult patients with moderately to severely active ...

Share on Pinterest Humira will soon have a citrate-free biosimilar available on the market. Humira (adalimumab) is a popular medication used to treat various inflammatory conditions including ...

Many existing treatments for inflammatory bowel disease, like Remicade and Humira, work by blocking inflammatory cytokines such as tumor necrosis factor (TNF) and interleukins IL-12 and IL-23, which ...

As widely expected by the pharmaceutical industry, seven pharmaceutical companies are releasing biosimilars of AbbVie's Humira. Boehringer Ingelheim's Cyltezo (adalimumab-adbm), an interchangeable ...

Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Sales of AbbVie's Humira are plummeting as the once-top-selling drug fights ...